Too many reasons for a reply here, but overall the common theme is lack of regulation giving pharma more power to play on their patent-derived monopolies. As f

Too many reasons for a reply here, but overall the common theme is lack of regulation giving pharma more power to play on their patent-derived monopolies. As for Switzerland, it's a small country with an economic model that doesn't scale/generalize. Even in Switzerland there's constant discussion about health care (insurance) being too expensive - though the biggest driver is wages not drug prices.